EuroPCR takes place in Paris, France at the Palais des Congrès from May 17 – 20.
Mitralign will be highlighted at the EuroPCR Innovators Day on May 16th, with Dr. Azeem Latib, from St. Rafaelle Hospital presenting the Trialign System for the treatment of tricuspid regurgitation. In addition, the company will sponsor a symposium on Thursday, May 19th chaired by Dr. Neil Moat, of the Royal Brompton Hospital, London, UK.
The symposium will be held from 13:35 – 14:35 in room 241. Mitralign personnel will be available in the Palais de Congrès at booth P13 located on the second floor.
Mitralign is the only company to provide a direct transcatheter annuloplasty system, designed to treat both functional mitral regurgitation (FMR) and functional tricuspid regurgitation (FTR).
The first application of this innovation, the Mitralign Percutaneous Annuloplasty System (MPAS) for FMR, earned CE Mark earlier this year. Trialign for FTR is being investigated in an early feasibility study in the US and is not approved for sale or distribution.
Tricuspid regurgitation occurs when the tricuspid valve fails to open and close properly, causing blood to flow backwards into the right atrium. If left untreated, TR can lead to heart enlargement and heart failure.
In the U.S. alone, there are an estimated 1.6 million patients suffering from TR4. It is estimated that 50% of patients with mitral regurgitation have moderate to severe tricuspid regurgitation5. TR is currently undertreated by surgery.
In the U.S. surgeons treat only 5,500 patients per year, most of them in conjunction with left heart surgeries. When treating the valves, surgeons choose repair 90% of the time versus replacement (10%).
